EGFR and non-small cell lung carcinoma: Multiple EGFR tyrosine kinases inhibitors (TKIs) such as erlotinib, gefitinib, afatinib, and osimertinib have been used in first-line treatment for advanced NSCLC patients with activating EGFR mutations [34].